NASDAQ$DH
Definitive Healthcare Corp · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Definitive Healthcare reported financial results for the fourth quarter and full fiscal year 2024, with revenue exceeding guidance.
Definitive Healthcare reported Q4 2024 revenue of $62.3 million, a 6% decrease from Q4 2023. The company experienced a net loss of $(84.7) million, significantly impacted by goodwill impairment charges of $97.1 million. Despite the net loss, adjusted net income increased to $12.6 million and adjusted EBITDA was $17.5 million, representing 28% of revenue.
- Q4 2024 revenue was $62.3 million, a 6% decrease year-over-year.
- Net loss for Q4 2024 was $(84.7) million, primarily due to $97.1 million in goodwill impairment charges.
- Adjusted Net Income for Q4 2024 increased to $12.6 million from $10.6 million in Q4 2023.
- Adjusted EBITDA for Q4 2024 was $17.5 million, representing 28% of revenue.
Headline financials
Revenue & EPS history
Definitive Healthcare · Revenue · Quarterly
$62.3M
Forward guidance
For the first quarter of 2025, Definitive Healthcare expects revenue between $55.5 million and $57.0 million, adjusted operating income between $7.5 million and $8.5 million, and adjusted EBITDA between $10.5 million and $11.5 million. For the full year 2025, revenue is projected to be between $230.0 million and $240.0 million, with adjusted EBITDA between $61.0 million and $65.0 million.
Tailwinds
- Q1 2025 Revenue expected to be between $55.5 million and $57.0 million.
- Q1 2025 Adjusted Operating Income expected to be between $7.5 million and $8.5 million.
- Q1 2025 Adjusted EBITDA expected to be between $10.5 million and $11.5 million, with a 19-20% margin.
- FY 2025 Revenue expected to be between $230.0 million and $240.0 million.
- FY 2025 Adjusted EBITDA expected to be between $61.0 million and $65.0 million, with a 26-28% margin.
Headwinds
- The company does not provide a quantitative reconciliation of forward-looking non-GAAP measures to GAAP due to high variability.
- Excluded items from non-GAAP measures, such as equity-based compensation and transaction expenses, may have a significant impact on future GAAP results.
- The variability and difficulty in predicting certain excluded items make a direct reconciliation impractical.
- Future expenses similar to those eliminated in non-GAAP presentations may be incurred.
- The forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2024
-3.2%
Avg return
Earnings day
-5.7%
Avg return
5 days after
-5.8%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+31.7%
Q1 2025
Best reaction
-34.3%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.2% | -2.0% | -5.2% | |
| Q4 2025 | -8.6% | -12.9% | -25.0% | |
| Q3 2025 | +11.9% | +2.6% | -6.4% | |
| Q1 2025 | +31.7% | +21.4% | +33.1% | |
| Q4 2024 | -34.3% | -43.7% | -40.2% | |
| Q3 2024 | -1.4% | +6.3% | +8.4% | |
| Q2 2024 | -1.4% | +5.1% | +21.6% | |
| Q1 2024 | -27.1% | -27.5% | -22.9% | |
| Q4 2023 | +2.3% | -4.2% | -13.3% | |
| Q3 2023 | +27.5% | +29.5% | +49.5% | |
| Q2 2023 | -4.0% | -6.2% | -21.2% | |
| Q1 2023 | +0.9% | -3.7% | +7.9% | |
| Q4 2022 | +3.5% | -1.6% | -11.5% | |
| Q3 2022 | -25.0% | -29.7% | -14.5% | |
| Q2 2022 | -16.3% | -18.6% | -35.7% | |
| Q1 2022 | -17.5% | -31.3% | -19.4% | |
| Q4 2021 | +7.6% | +13.6% | +14.0% | |
| Q3 2021 | -5.8% | +0.2% | -23.3% | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro